EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparison of 5‐Fluorouracil/Leucovorin and Capecitabine as Adjuvant Therapies in Biliary Tract Cancer

Tae Seung Lee, Young Hoon Choi, Jun Yeol Kim, Myeong Hwan Lee, Kyu-Hyun Paik, In Rae Cho, Woo Il Kwon, Sang Hyub Lee iD, In Seok Lee, Myung Ah Lee, Jin-Young Jang, Ji Kon Ryu iD und 2 weitere

Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1111/jgh.17044 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Tae Seung Lee und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seou…. Hauptthemen laut MEDLINE: Capecitabine, Fluorouracil, Leucovorin, Biliary Tract Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prognosis of biliary tract cancer (BTC) is poor, and recurrence rates remain high even after curative resection. This study aimed to compare the efficacy and safety of capecitabine and 5‐fluorouracil/leucovorin (FL) as adjuvant treatments following curative resection in patients with BTC.

Methods

We retrospectively reviewed the medical records of patients with BTC (including gallbladder and extrahepatic and intrahepatic bile duct cancers) who underwent curative surgical resection and adjuvant chemotherapy between 2011 and 2023. The recurrence‐free survival, overall survival, and adverse events were investigated between the two groups.

Results

Of the 263 patients, 85 and 178 received capecitabine and FL, respectively. The recurrence‐free survival and overall survival did not show statistically significant differences between the capecitabine and FL groups. After propensity score matching, the capecitabine group showed significantly longer overall survival (median, NA [52 − NA] vs. 43 months [32 − NA], p = 0.032). Although severe adverse events did not differ between both groups (29.4% vs. 20.2%, p = 0.135), overall adverse events, including anemia, thrombocytopenia, hand–foot syndrome, and skin color change, were significantly more frequent in the capecitabine group (90.6% vs. 57.9%, p < 0.001). After propensity score matching, severe adverse events (30.3% vs. 14.5%, p = 0.032) and overall adverse events (90.8% vs. 65.8%, p < 0.001) were significantly more frequent in the capecitabine group.

Conclusion

In patients with curatively resected BTC, capecitabine demonstrated superior efficacy in prolonging overall survival, whereas FL had a more favorable safety profile with fewer adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CapecitabineFluorouracilLeucovorinBiliary Tract NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedChemotherapy, AdjuvantTreatment OutcomePropensity ScoreAdultSurvival Rate

Stichwörter der Autor:innen

5‐fluorouracil/leucovorinadjuvantbiliary tract cancercapecitabine

Substanzen

CapecitabineFluorouracilLeucovorin

Autor:innen und Institutionen

  • Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, College of Medicine, Catholic University of Korea, Seoul, South Korea.
  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Sang Hyub Lee, Ji Kon Ryu, Woo Hyun Paik

Zitieren

APA

Lee, T. S., Choi, Y. H., Kim, J. Y., Lee, M. H., Paik, K. H., Cho, I. R., Kwon, W. I., Lee, S. H., Lee, I. S., Lee, M. A., Jang, J. Y., Ryu, J. K., Kim, Y. T., & Paik, W. H. (2025). Comparison of 5‐Fluorouracil/Leucovorin and Capecitabine as Adjuvant Therapies in Biliary Tract Cancer. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.17044

Vancouver

Lee TS, Choi YH, Kim JY, Lee MH, Paik KH, Cho IR, et al. Comparison of 5‐Fluorouracil/Leucovorin and Capecitabine as Adjuvant Therapies in Biliary Tract Cancer. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.17044

BibTeX
@article{Lee2025,
  author = {Lee, Tae Seung and Choi, Young Hoon and Kim, Jun Yeol and Lee, Myeong Hwan and Paik, Kyu-Hyun and Cho, In Rae and Kwon, Woo Il and Lee, Sang Hyub and Lee, In Seok and Lee, Myung Ah and Jang, Jin-Young and Ryu, Ji Kon and Kim, Yong-Tae and Paik, Woo Hyun},
  title = {Comparison of 5‐Fluorouracil/Leucovorin and Capecitabine as Adjuvant Therapies in Biliary Tract Cancer},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1111/jgh.17044}
}
Kostenlos starten →